The effect of oral administration of brewer's yeast on resistance to infectious diseases was studied in laboratory animals. It was shown that there was a significantly increased enhancement of resistance to seasonal respiratory and enteric infections in rhesus monkeys. Similarly, enhanced resistance to experimental chronic infections was observed in mice after yeast administration. A 2-week lag occurred between the initiation of yeast treatment and the expression of enhanced resistance. Study of the mechanism of the yeast-induced enhancement of resistance to infection leads to the conclusion that it is based on in vivo stimulation of phagocytosis, as measured by the "phagocytic index." No effect of brewer's yeast on circulating antibody levels was detected.
Host resistance to invading microorganisms is based on two types of immune response: an acquired one, to which specificity is usually attributed; and an innate, or nonspecific, response, resulting from the participation of several components in the interaction between host and pathogen (24) . Among the latter, inflammation (5), phagocytosis (13) , natural antibodies (16) , properdin (19) , and complement (12) are considered to be the major participants. The nonspecific resistance of the host may be modulated by different agents of a nonspecific nature (8, 22) . Recognition of the importance of enhancing agents in prophylaxis and therapy has spurred the search for these effectors. Among these, compounds like endotoxin (18) , BCG (14) , polynucleotides (4) , and zymosan (11) have been widely studied.
In the present study, we describe some of our experiments in the enhancement of nonspecific resistance to infectious diseases in laboratory animals by oral administration of brewer's yeast. A mechanism for this stimulation is suggested, and the relationship of brewer's yeast to other resistance-enhancing agents is discussed.
MATERIALS AND METHODS Monkeys. Monkeys of strain Macaca mulata, imported from India, were quarantined on arrival at our Institute for 6 weeks. Monkeys of both sexes, weighing 2 to 2.5 kg, were caged singly and fed a diet consisting of cereal-pelleted animal food (Ambar Ltd., Israel), seasonal vegetables, fruit, and a multivitamin preparation (Rafa-9, Rafa Laboratories Ltd., Jerusalem, Israel). Sick animals were given appropriate antibiotic and supportive treatment.
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Mice. Female mice (25 to 35 g) of an inbred R m strain and a random-bred Swiss albino strain were used. They were fed pelleted chow (Ambar Ltd., Israel) and water ad libitum.
Brewer's yeast. Saccharomyces cerevisiae, dried, in tablets each containing 500 mg, was obtained from Pharmaceutical Products "Rekah" Ltd., Azor; or Taro Pharmaceutical Industries Ltd., Haifa. The daily doses employed were 500 mg per monkey or 35 mg per mouse, administered per os and mixed with food.
Microorganisms. Staphylococcus aureus strain Toro, obtained from Lepetit and Co., Italy, was grown for 18 h at 37 C on nutrient agar (Difco).
Yersinia pestis. An avirulent strain TRU unable to synthesize VW antigen (7) and vaccine strain EV 76, which develops resistance to phagocytosis upon incubation at 37 C (15) , were grown at 28 C for 48 h on blood agar base (Difco) containing 2.5% hemolized rabbit blood.
Brucella melitensis. Rev. I. vaccine strain (9) was grown for 48 h at 37 C on Trypticase soy agar (BBL) supplemented with 3% glycerol and 5 tsg of thiamine per ml.
All microorganisms were harvested and washed twice in saline shortly before inoculation into animals. Antiserum to mouse phagocytic cells. A preparation of antiserum to mouse phagocytic cells was prepared in rabbits. Mouse peritoneal phagocytic cells were mobilized by i.p. injection of 1 ml of saline. The exudate cells were harvested 6 and 24 h later in cold Tyrode solution to obtain polymorphonuclear cells and macrophages, respectively. The cell suspensions were diluted to 1.5 x 107 cells/ml. The rabbits were immunized by three intravenous injections of 1 ml of the freshly harvested cells, at intervals of 1 week, followed by two booster doses at monthly intervals. This antiserum completely lysed mouse polymorphonuclear and macrophage cells on incubation at 37 C for 1 h, and did not affect the microorganisms used in these experiments.
Assay of antibody formation. The assay was based on quantitation of the primary response after i.p. administration of a single dose of 3 mg of bovine gamma globulin (Mann Research Laboratories) into groups of mice. Antibody formation was measured in terms of concentration of circulating antibodies and length of induction period. Seven and 12 days after antigen injection, blood samples were collected and the sera were tested individually by the passive hemagglutination method of Boyden (3).
RESULTS
Effect of brewer's yeast on resistance to infection in newly arrived, quarantined monkeys. Fifty newly arrived monkeys were included in the experiment. On the day of arrival, they were randomly divided into two groups: control, comprising 35 animals, and the experimental group of 15 animals. The experimental animals were given 0.5 g of brewer's yeast per os daily. Yeast treatment began on the first day of quarantine and was continued throughout the experiment.
The effect of brewer's yeast was measured by comparison of morbidity and mortality rates as well as by duration of illness in experimental and control monkeys. Figure 1 illustrates the biphasic nature of the incidence of morbidity in the control group. The first peak occurred within the first 2 weeks of quarantine, followed by a short period of quiescence and then a second morbidity peak. Moreover, all deaths were clustered around the first peak of morbidity (Table 1) . Comparison of yeast-treated and control monkeys (Table 1 and Fig. 1 ) indicates no significant difference either in mortality and morbidity rates or in the duration of infection during the first 2 weeks of treatment. However, in the period after the first peak of disease, the yeast-treated monkeys exhibited a high degree of resistance to infection. Out of the 13 survivors in the treated group, none were sick, whereas 40% in the control group became ill. This difference is statistically highly significant (P < 0.001). On the basis of these results, it was concluded that oral administration of brewer's yeast to monkeys significantly enhances their resistance to seasonal infections. This enhanced resistance is manifested only 2 weeks after initiation of treatment; thereafter, it persists at a constant high level for the duration of treatment. Effect on phagocytosis. In an attempt to clarify the mechanism of enhancement of resistance to infection in the experimental animals, we tested the effect of orally administered brewer's yeast on in vivo phagocytosis of various microorganisms. In a typical experiment, Y. pestis strain TRU cells, freshly harvested and washed in saline, were injected i.p. into 60 strain R III mice at a concentration of 2.5 x 108 per animal. The experimental group comprised 30 mice treated orally with brewer's yeast for 2 weeks before inoculation. The 30 control mice did not receive yeast treatment. Similar experiments were performed using two other microorganisms, Y. pestis EV 76 (5 x 107 cells per mouse) and S. aureus (109 cells per mouse). Phagocytic activity at different time intervals after inoculation in the yeast-treated and control animals was measured as described in Materials and Methods by: (i) rate of clearance of bacteria from the peritoneal cavity; and (ii) rate of ingestion by phagocytic cells in the peritoneal cavity. Rates of clearance and ingestion were correlated with the corresponding cellular response in the peritoneal exudate, measured by the number of mononuclear and polymorphonuclear cells. The experiments were replicated twice; data for a representative experiment are given in Fig. 2 and Table 3 .
These experiments indicate that orally administered brewer's yeast enhanced phagocytic activity in mice, as manifested by a statistically significant increase in the rate of clearance of different microorganisms from the peritoneal cavity. Phagocytic activity following i.p. injection of microorganisms can be divided into two phases: the initial phase of rapid clearing which may be attributed to the activity of peritoneal macrophages present at time of injection (Fig.  2) ; and a slower activity (second phase) which occurs between 2 and 3 h after inoculation, coinciding with the influx of polymorphonuclear cells into the peritoneum (Fig. 3) . The enhancement of phagocytic activity in yeast-treated mice was more pronounced during the second phase (Fig. 2) .
Also, the rate of ingestion was significantly higher in the treated animals. This was true for S. aureus but was particularly apparent in Y. pestis EV 76, known to develop resistance to phagocytosis at 37 C. (Fig.  3) . The number of phagocytic cells in the peritoneal cavity at any given time after inoculation is the result of cell influx, migration to (Table 4) show that brewer's yeast had no effect on the primary response in antibody synthesis, both with regard to antibody concentration and length of the induction period.
DISCUSSION The experiments described demonstrate that brewer's yeast administered per os to experimental animals enhances nonspecific resistance to infection. This enhanced resistance was exhibited against a variety of agents, ranging from microorganisms causing seasonal infections of Our results suggest that the mechanism responsible for the enhancing effect of orally administered yeast on resistance to disease is based on an increase in the rate of phagocytosis. This is not unique to this system, but is found also for some other resistance-enhancing agents, e.g., the activation of the "angry macrophages" by BCG (14) . The effect has also been attributed to zymosan, as mentioned earlier.
We did not detect any enhancing effect upon formation of circulating antibody, as was demonstrated in the primary antibody response to injection of bovine gamma globulin in mice, as well as in the lack of increase in antibrucella agglutinin in mice recovering from experimental brucellosis. Although more experimental data will be needed to establish this contention, it is suggested that brewer's yeast exerts an enhancing effect on mechanisms related to cellular resistance rather than on those based on circulating antibody. 
